Abstracts tagged "Disease Activity"

Abstract Number: 2532 • 2018 ACR/ARHP Annual Meeting
The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry
Sadettin Uslu¹, Gerçek Can¹, Soner Senel², Ediz Dalkiliç³, Nevsun Inanc⁴, Servet Akar⁵, Sinem Burcu Kocaer¹, Merih Birlik¹, Sedat Capar⁶, Nurullah Akkoc⁷ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ³Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁶Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁷Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Biosimilar infliximab (CT-P13) has been used to treat patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Turkey since 2013.The…
Abstract Number: 2887 • 2018 ACR/ARHP Annual Meeting
Chronic Pain and Assessment of Pain Sensitivity in Patients with Established Axial Spondyloarthritis – a Cross-Sectional Study
Elisabeth Mogard¹, Tor Olofsson², Stefan Bergman³, Ann Bremander⁴, Lars Erik Kristensen⁵, Jack Kvistgaard Olsen⁶, Johan K Wallman⁷ and Elisabet Lindqvist⁸, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Faculty of Medicine and Skåne University Hospital, Lund, Sweden, ²Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ³University of Gothenburg, Gothenburg, Sweden, ⁴Spenshult Research and Development Center, Halmstad, Sweden, ⁵Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁶Department of Rheumatology, Copenhagen University Hospital, Fredriksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁷Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ⁸Department of Clinical Sciences Lund,Section of Rheumatology, Lund University, Faculty of Medicine and Skåne University Hospital, Lund, Sweden
Background/Purpose: Pain remains a common and debilitating symptom in arthritis, despite good options to treat inflammation. In axial spondyloarthritis (axSpA), data on chronic pain remain…
Abstract Number: 210 • 2018 ACR/ARHP Annual Meeting
Changes in Alcohol Use in Patients with Rheumatoid Arthritis: Associations with Disease Activity, Health Status, and Mortality
Joshua Baker¹, Harlan Sayles², Bryant R. England³, Ted R. Mikuls⁴ and Kaleb Michaud⁵, ¹Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Prior studies observed better disease control, quality of life, and physical function among patients with rheumatoid arthritis (RA) who drink alcohol. These studies may…
Abstract Number: 533 • 2018 ACR/ARHP Annual Meeting
Association between Inflammation and Changes in Kidney Function in Patients with Early Rheumatoid Arthritis
Ganna Prytkova¹, Dmytro Rekalov² and Daryna Nikitina¹, ¹Rheumatology, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine, ²Department of Internal Diseases, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine
Background/Purpose: One of the most severe visceral manifestations of RA is nephropathy. The key symptoms of renal dysfunction (RD) are microalbuminuria (MA), β-2-microglobulinuria (β-2M), reduced…
Abstract Number: 1060 • 2018 ACR/ARHP Annual Meeting
Variation in the Synovial Fluid Metabolome According to Disease Activity in Rheumatoid Arthritis
Joong Kyong Ahn¹, Jiwon Hwang², Jaejoon Lee³, Eun-Mi Koh³ and Hoon-Suk Cha³, ¹Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Internal Medicine, National Police Hospital, Seoul, Korea, Republic of (South), ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease characterized by persistent inflammation and joint damage with a heterogeneous course and different pathogenic mechanisms. Metabolomics,…
Abstract Number: 1500 • 2018 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients
Nadia MT Roodenrijs¹, Maria JH de Hair¹, Gill Wheater², Mohsen Elshahaly³, Janneke Tekstra¹, Y.K. Onno Teng⁴, Floris PJG Lafeber¹, Ching Chang Hwang⁵, Xinyu Liu⁶, Eric H. Sasso⁵ and Jacob van Laar¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Department of Biochemistry, The James Cook University Hospital, Middlesbrough, UK, Middlesbrough, United Kingdom, ³Department of Rheumatology & Rehabilitation, Suez Canal University, Ismailia, Egypt, Ismailia, Egypt, ⁴Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁵Crescendo Bioscience, San Francisco, CA, USA, South San Francisco, CA, ⁶Crescendo Bioscience, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score was developed to objectively measure disease activity for patients with rheumatoid arthritis (RA).1 The MBDA score is calculated…
Abstract Number: 1732 • 2018 ACR/ARHP Annual Meeting
Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
Sabina Oreska^1,2, Maja Spiritovic^1,3, Petr Cesak⁴, Michal Cesak⁵, Hana Storkanova^1,2, Hana Smucrova¹, Barbora Hermankova^1,3, Barbora Sumova^1,2, Olga Ruzickova^1,6, Herman F Mann^1,7, Karel Pavelka^1,2, Ladislav Šenolt^1,2, Jiri Vencovsky^1,8, Radim Becvar^1,2 and Michal Tomcik^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁸Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement in systemic sclerosis (SSc) can have a negative impact on body…
Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Filip van Den Bosch¹, Andrew Ostor², Patrick Zueger³, Meijing Wu³, Ivan Lagunes Galindo³ and Siegfried Wassenberg⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Cabrini Medical Center, Melbourne, Australia, ³AbbVie Inc., North Chicago, IL, ⁴Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…
Abstract Number: 2570 • 2018 ACR/ARHP Annual Meeting
Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast
Philip J. Mease¹, Frank Behrens², Dafna D Gladman³, Arthur Kavanaugh⁴, Michele Brunori⁵, Lichen Teng⁵, Benoit Guerette⁵, Rubén Queiro⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California, San Diego, School of Medicine, La Jolla, CA, ⁵Celgene Corporation, Summit, NJ, ⁶Rheum-Derm Unit, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: The ability to predict responses to apremilast (APR) could impact treatment decisions. This post-hoc analysis was conducted to (1) assess the predictive values of…
Abstract Number: 2889 • 2018 ACR/ARHP Annual Meeting
Inhibition of Radiographic Progression and Correlation with Changes in Composite Indices of Disease Activity in Patients with Active Psoriatic Arthritis Treated with Intravenous Golimumab, As Measured in a Phase III Trial
Philip J. Mease¹, Shelly Kafka², Soumya D Chakravarty³, Diane D. Harrison⁴, Kim Hung Lo⁴, Stephen Xu⁴, Elizabeth C Hsia⁵ and Arthur Kavanaugh⁶, ¹Swedish Medical Centre and University of Washington, Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, ⁶University of California, San Diego, School of Medicine, La Jolla, CA
Background/Purpose: GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM), an anti-tumor necrosis factor alpha (TNFα) monoclonal antibody, in adult patients (pts) w/…
Abstract Number: 213 • 2018 ACR/ARHP Annual Meeting
Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease
Annette de Thurah^1,2, Ina Trolle Andersen³, Andreas Bugge Tingaard⁴, Josephine Therkildsen⁵, Anders Hammerich Riis³, Morten Böttcher⁵ and Ellen-Margrethe Hauge^6,7, ¹Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁵Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after…
Abstract Number: 536 • 2018 ACR/ARHP Annual Meeting
Prevalence and Relative Factors for Frailty in Patients with RA from a Prospective Observational Study
Masahiro Tada¹, Yutaro Yamada², Koji Mandai³ and Noriaki Hidaka⁴, ¹Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan, ²Orthopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orthopaedic surgery, Osaka City General Hospital, Osaka, Japan
Prevalence and relative factors for frailty in patients with RA from a prospective observational study Background/Purpose: Frailty is defined as degradation of physical and cognition…
Abstract Number: 1088 • 2018 ACR/ARHP Annual Meeting
Pro-Inflammatory and Regulatory Soluble Mediator Pathways Vary between African American and European American SLE Patients
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women, and is associated with periods of elevated and suppressed clinical symptoms. SLE…
Abstract Number: 1501 • 2018 ACR/ARHP Annual Meeting
Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate
Tate Johnson¹, Bryant R. England², Harlan Sayles¹, Geoffrey M. Thiele¹, Ted R. Mikuls³ and James R. O'Dell⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Multi-Biomarker Disease Activity (MBDA) score was developed to provide an objective measure of rheumatoid arthritis (RA) disease activity. Demonstrating moderate correlations with conventional…
Abstract Number: 1760 • 2018 ACR/ARHP Annual Meeting
Fungal Composition of the Nasal Mucosa in Patients with Granulomatosis with Polyangiitis
Rennie L. Rhee¹, Antoine G. Sreih¹, Catherine E. Najem², Peter C. Grayson³, Chunyu Zhao⁴, Kyle Bittinger⁴, Ronald Collman⁵ and Peter A. Merkel⁶, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ⁴Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: While prior studies have demonstrated that granulomatosis with polyangiitis (GPA; Wegener’s) is associated with an altered composition of nasal bacteria and that use of…